Abstract | RATIONALE: The coexistence of the extranidal marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) and multiple myeloma (MM) is an exceedingly rare situation. The rare situation precludes any evidence-based guidelines for MZL or MM. PATIENT CONCERNS AND DIAGNOSES: INTERVENTIONS AND OUTCOMES: LESSONS: The case demonstrated clinical complexity and the importance of the detailed assessment. The case and literature review demonstrated the value of detecting light chain-restricted plasmacytic differentiation for the treatment of MZL lymphoma with rituximab plus lenalidomide or bortezomib.
|
Authors | Shangjin Yin, Kuangguo Zhou, Zhiqiong Wang, Duanhao Gong, Wei Huang |
Journal | Medicine
(Medicine (Baltimore))
Vol. 102
Issue 4
Pg. e32801
(Jan 27 2023)
ISSN: 1536-5964 [Electronic] United States |
PMID | 36705370
(Publication Type: Review, Case Reports, Journal Article)
|
Copyright | Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. |
Chemical References |
- Rituximab
- Lenalidomide
- Bortezomib
|
Topics |
- Humans
- Lymphoma, B-Cell, Marginal Zone
(complications, drug therapy, diagnosis)
- Rituximab
(therapeutic use)
- Multiple Myeloma
(complications, diagnosis)
- Lenalidomide
(therapeutic use)
- POEMS Syndrome
(complications, diagnosis)
- Bortezomib
(therapeutic use)
- Thymus Neoplasms
|